Bruker (NASDAQ:BRKR) Price Target Raised to $64.00

Bruker (NASDAQ:BRKR) had its price objective increased by analysts at Citigroup from $53.00 to $64.00 in a note issued to investors on Thursday, MarketBeat.com reports. The brokerage presently has a “hold” rating on the medical research company’s stock. Citigroup‘s target price indicates a potential upside of 4.39% from the company’s current price.

BRKR has been the topic of a number of other research reports. UBS Group began coverage on Bruker in a report on Wednesday, September 9th. They set a “neutral” rating and a $65.00 price objective on the stock. Zacks Research cut Bruker from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 2nd. Leerink Partners increased their price target on Bruker from $80.00 to $85.00 and gave the company an “outperform” rating in a report on Thursday. TD Cowen lifted their price target on shares of Bruker from $60.00 to $62.00 and gave the company a “hold” rating in a research report on Tuesday, October 13th. Finally, The Goldman Sachs Group upgraded shares of Bruker from a “strong sell” rating to a “strong-buy” rating in a research note on Monday, September 21st. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Bruker has an average rating of “Moderate Buy” and an average price target of $60.57.

Bruker Stock Up 5.6%

NASDAQ BRKR traded up $3.25 during trading on Thursday, reaching $61.31. The company’s stock had a trading volume of 2,012,693 shares, compared to its average volume of 2,182,166. The company has a current ratio of 1.85, a quick ratio of 0.92 and a debt-to-equity ratio of 0.76. The stock has a market capitalization of $9.34 billion, a PE ratio of -55.74, a PEG ratio of 1.70 and a beta of 1.26. Bruker has a 1-year low of $32.37 and a 1-year high of $68.98. The business has a 50-day moving average price of $59.01 and a 200-day moving average price of $50.59.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Wednesday, November 4th. The medical research company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.42 by $0.14. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The business had revenue of $874.00 million for the quarter, compared to the consensus estimate of $865.16 million. During the same quarter last year, the firm earned $0.45 EPS. Bruker’s revenue for the quarter was up 1.6% on a year-over-year basis. On average, research analysts forecast that Bruker will post 2.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, VP Mark Munch sold 2,000 shares of the stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total value of $105,740.00. Following the completion of the transaction, the vice president owned 134,806 shares of the company’s stock, valued at $7,127,193.22. This represents a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 27.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Bruker

Several large investors have recently modified their holdings of the stock. Essential Partners LLC acquired a new position in shares of Bruker in the 1st quarter worth approximately $36,000. Global Retirement Partners LLC acquired a new position in Bruker during the second quarter worth $38,000. Provenance Wealth Advisors LLC acquired a new position in Bruker during the third quarter worth $52,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Bruker by 532.9% during the first quarter. EverSource Wealth Advisors LLC now owns 1,500 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 1,263 shares during the period. Finally, Root Financial Partners LLC bought a new position in shares of Bruker during the third quarter valued at $57,000. 79.52% of the stock is currently owned by institutional investors.

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, molecules and biological processes. Its technologies support research, discovery and quality control in fields including life sciences, pharmaceutical development, chemical analysis, materials science, environmental testing and clinical research.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, infrared and Raman spectroscopy instruments, X-ray analysis equipment, microscopy and nanoanalysis systems, and preclinical imaging technologies.